Citation Impact
Citing Papers
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor
2011
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
2012 Standout
Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden
2004
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
2008
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density<SUBTITLE>The Women's Health Initiative Randomized Trial</SUBTITLE>
2003 Standout
Child abuse: Adolescent records vs. adult recall
1990 Standout
Thiazolidinediones
2004 Standout
Mammographic Density and the Risk and Detection of Breast Cancer
2007 Standout
Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease
2009
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
2010
Osteoporosis
2019 Standout
Contributions of estrogen to ER-negative breast tumor growth
2006
Design and methods of the Raloxifene Use for The Heart (RUTH) study
2001
MANAGEMENT OF ENDOCRINE DISEASE: The burden of Cushing's disease: clinical and health-related quality of life aspects
2012
Osteoporosis
2006
Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole?
2013
A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease
2012
Small cerebellar cortex volume in patients with active Cushing's syndrome
2014
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Chronic inflammation in the etiology of disease across the life span
2019 Standout
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
2009
Use of doping agents, particularly anabolic steroids, in sports and society
2008 Standout
Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy
2002 Standout
Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
2001 StandoutNobel
Is dehydroepiandrosterone a hormone?
2005
Diagnosis of osteoporosis and assessment of fracture risk
2002 Standout
Primary Care for Survivors of Breast Cancer
2000
Endometriosis
2009 Standout
Cushing's syndrome
2015 Standout
Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>
2006
Cabergoline monotherapy in the long-term treatment of Cushing's disease
2010
Medical Treatment of Cushing's Disease
2013
Intervention thresholds for osteoporosis in the UK
2004
Nelson's syndrome
2010
Combined Screening With Ultrasound and Mammography vs Mammography Alone in Women at Elevated Risk of Breast Cancer
2008 Standout
Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation
2001 Standout
Pros and cons of screening for occult Cushing syndrome
2011
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
2005
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study
2011
Intervention thresholds for osteoporosis
2002
Osteoporosis: now and the future
2011 Standout
Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures
2004
Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial
2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
Treatment of postmenopausal osteoporosis
2002
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial
2001
Systematic review of bisphosphonates for hypercalcaemia of malignancy
2004
Epidemiology of breast cancer
2001
Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature
2005
Uterine fibroids
2001 Standout
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
2009 Standout
Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms
2014
Assessing the Risk of Breast Cancer
2000
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
2013
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
2009 Standout
Osteoclast differentiation and activation
2003 StandoutNature
Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers
2013
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
PPARγ signaling and metabolism: the good, the bad and the future
2013 Standout
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy
2003
Estrogen plus Progestin and the Risk of Coronary Heart Disease
2003 Standout
Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center
2012
Similarities and distinctions in the mode of action of different classes of antioestrogens.
2000
Outcome of Bilateral Adrenalectomy in Cushing's Syndrome: A Systematic Review
2013
Pasireotide (SOM230): Development, mechanism of action and potential applications
2007
Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance
2005
Modern Synthetic Methods for Fluorine‐Substituted Target Molecules
2004 Standout
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
2003
At what hip fracture risk is it cost-effective to treat?
2006
The Impact of Monitoring on Adherence and Persistence with Antiresorptive Treatment for Postmenopausal Osteoporosis: A Randomized Controlled Trial
2004
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases
2008
The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics
2011
Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study
2004
Breast cancer risk assessment models
2002
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
2009 Standout
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas
2011
Quantitative Assessment of Mammographic Breast Density: Relationship with Breast Cancer Risk
2004
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
2003
Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study
2000
Side Effects of Adjuvant Treatment of Breast Cancer
2001
Preservation of Fertility in Patients with Cancer
2009 Standout
Prevention of falls and consequent injuries in elderly people
2005 Standout
Roles of PPARs in health and disease
2000 StandoutNature
Oestrogen exposure and breast cancer risk
2003
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
New developments in the medical treatment of Cushing's syndrome
2012
Cancer of the Ovary
2004 Standout
Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club
2005
Approach to the Cushing's Disease Patient With Persistent/Recurrent Hypercortisolism After Pituitary Surgery
2013
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials
2015 Standout
Bone Resorption by Osteoclasts
2000 StandoutScience
Selective Estrogen Receptor Modulators
2004
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
2008
A Structural and in Vitro Characterization of Asoprisnil: A Selective Progesterone Receptor Modulator
2007
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 1. Receptor Interactions
2003
Noncardiovascular disease outcomes during 6.8 years of hormone therapy. heart and estrogen/progestin replacement study follow-up (HERS II)
2002
Quality of Life and Other Outcomes in Children Treated for Cushing Syndrome
2013
Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
2011
The Epidemiology of Venous Thromboembolism
2003 Standout
Coexpression of Dopamine and Somatostatin Receptor Subtypes in Corticotroph Adenomas
2009
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective Studies
2002 Standout
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
2002 Standout
A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis.
1999
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance
2008
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling
2005 StandoutScience
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis
2005
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents
2003
Preclinical Evidence for Therapeutic Efficacy of Selective Estrogen receptor Modulators for Uterine Leiomyoma
2000
Therapeutic Approaches to Bone Diseases
2000 Science
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
2006 StandoutScience
A systematic review of the role of bisphosphonates in metastatic disease
2004
Works of J. E. Glusman being referenced
Treatment of Pituitary-Dependent Cushing’s Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial
2008
Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.
1993
Effects of high dose raloxifene in selected patients with advanced breast carcinoma
2000
Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire
2008
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women
1999
Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study
2006
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial
2000